Longidase ® has hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulating and moderately expressed anti-inflammatory properties.
The prolongation of the action of the enzyme is achieved by covalent binding of the enzyme with a physiologically active polymeric carrier (azoxime). Longidase ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor - alpha), increases the humoral immune response and resistance of the body to infection.
The expressed antifibrotic properties of Longidase are provided by the conjugation of hyaluronidase with the carrier, which significantly increases the enzyme's resistance to denaturing effects and the action of inhibitors: the enzymatic activity of Longidase persists with heating to 37 ° C for 20 days, while the native hyaluronidase in the same conditions, loses its activity during the day. In the preparation of Longidase®, a simultaneous local presence of the hyaluronidase enzyme and a carrier capable of binding the enzyme inhibitors and collagen synthesis stimulants released during the hydrolysis of matrix components (iron ions, copper ions, heparin, etc.) is ensured. Thanks to these properties, Longidase® has not only the ability to depolymerize the matrix of connective tissue in fibro-granulomuliasis formations, but also to inhibit the reverse regulatory reaction directed to the synthesis of connective tissue components.
The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulphate), which form the basis of the matrix of connective tissue. As a result of depolymerization (disruption of the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions, temporarily increases the permeability of tissue barriers, facilitates fluid movement in the intercellular space, increases the elasticity of the connective tissue, which manifests itself in reducing swelling of the tissue, flattening of scars, increasing the volume of movement of joints, reducing contractures and preventing their formation, reducing the adhesion process. Biochemical, immunological, histological and electron microscopic studies have shown that Longidase® does not damage normal connective tissue, but causes destruction of the connective tissue that has changed in composition and structure in the field of fibrosis.
Longidase ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and common allergic reactions.
The use of Longidase at therapeutic doses during or after surgical treatment does not cause a worsening of the course of the postoperative period or the progression of the infectious process; does not slow down the restoration of bone tissue.